CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced favorable safety and efficacy results from a Phase 1b study of IMO-2055, a TLR9 agonist, in combination with Tarceva® and Avastin® in thirty-six patients with advanced non-small cell lung cancer (NSCLC) who have previously failed one or more prior therapies. In this trial, the combination of IMO-2055 with Tarceva and Avastin was well tolerated. Thirty-three patients were evaluable for efficacy, and showed a disease control rate of 79%, a median progression-free survival of 5.6 months and a median overall survival of 16 months.
